Inve India ▾

Kwality Pharmaceuticals share price & results

Kwality Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Amritsar-based CDMO exporting generic & biologic formulations to 70+ countries via out-licensing.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue162 ₹ crore+45.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin25.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit26.0 ₹ crore+116.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity27.56 %+6.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-5.71 %−13.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)37.91 %+15.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 1 judged target kept · 18 open · verdicts reflect calls analysed to Q1 FY27.

Kwality Pharmaceuticals Limited management guidance track record on Inve: 19 targets tracked across analysed earnings calls (0 achieved, 1 missed, 18 open).

TargetOriginal wordingSaidLatest callVerdict
Q1 FY27 Revenue₹150 crores to ₹160 crores
Call transcript, Q4 FY26 · 19 May 2026		Q4 FY26Q1 FY27:The Q1 FY27 earnings summary did not provide the actual consolidated revenue figure for the quarter, making it impossible to verify if the guided range of ₹150-160 crores was met.
Call transcript, Q1 FY27 · 10 Aug 2026		Ghosted
FY27 Revenue₹650 crores
Call transcript, Q4 FY26 · 19 May 2026		Q4 FY26Q1 FY27:Management revised the FY27 revenue guidance upwards to 'plus INR700 crores', citing strong performance expectations and new registrations.
Call transcript, Q1 FY27 · 10 Aug 2026		Revised Up
FY27 PAT₹100 crores
Call transcript, Q4 FY26 · 19 May 2026		Q4 FY26Q1 FY27:Management revised FY27 revenue guidance upwards to over ₹700 crores while maintaining the EBITDA margin guidance of 26-27%. While a new PAT target was not explicitly stated, the higher revenue base suggests the ₹100 crore PAT target remains achievable.
Call transcript, Q1 FY27 · 10 Aug 2026		On Track

Source: Inve Guidance Tracker for Kwality Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Kwality Pharmaceuticals Limited's 19 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 16 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹3,599.4 +3.98% · +₹137.7

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +293.4% 1Y

₹1.0k₹2.0k₹3.0k₹4.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q4 FY26 — 19 May 2026Q1 FY27 — 10 Aug 2026

1Y: ₹915 on 24 Oct 2025 → ₹3,599.4. High ₹3,844.9 (21 Sept 2026), low ₹838.2 (11 Nov 2025).

Previous close
₹3,461.7
Market cap
₹3.6k Cr
52-week range
₹838.2 – ₹3,844.9
One year
+297.75%
Price to earnings (TTM to Jun 2026)
43.80×
Return on equity (TTM to Jun 2026)
27.56%

Overview

Symbol
NSE:KPL
Exchange
NSE
Currency
INR

What Kwality Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Kwality Pharmaceuticals develops and manufactures complex generic formulations — tablets, capsules, injectables, oncology and biologic products — across six dedicated manufacturing units spread over its Amritsar and Himachal Pradesh campuses. It earns primarily through an asset-light out-licensing and supply model, registering and selling its formulations through 100+ partner clients across LATAM, MENA, Europe, Asia and Africa, supplemented by direct CDMO (contract development and manufacturing) partnerships for global pharma companies. Its plants hold EU-GMP, PIC/S and WHO-GMP accreditations, and it is expanding into biosimilars (starting with an erythropoietin biosimilar) and monoclonal antibodies through in-house R&D.

Segments

  • Out-Licensing & Supply
  • CDMO (Contract Development & Manufacturing)
Manufacturing units
6 dedicated units (General, Beta Lactam, Oncology, Cephalosporins, Biologics, Hormones-under construction) across 2 campuses (Amritsar & Himachal Pradesh)
EU-GMP approved units
4 of 5 operating manufacturing units
Employees
1,700+, including 80+ in R&D
Countries served (exports)
70+ countries
Product portfolio
1000+ formulations across 25+ therapeutic areas
Global out-licensing clients
100+ clients across LATAM, MENA, Europe, Asia & Africa
Founded 1983Headquarters Amritsar, Punjab, IndiaEmployees 1,700

How the price took the results

close before → close after

Q1 FY27
+20.0%
10 Aug
Q4 FY26
+9.0%
19 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Kwality Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Kwality Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Kwality Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.